Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Increased Enforcement On Functional Foods Triggers Class Action Risk

This article was originally published in The Tan Sheet

Executive Summary

Functional foods increasingly are vulnerable to costly class action lawsuits as regulators crack down on advertising claims in this previously oft-ignored category.
Advertisement

Related Content

Embria Studies FDA Expectations Before Successful EpiCor NDI
Embria Studies FDA Expectations Before Successful EpiCor NDI
Dannon's FTC Settlement Requires FDA Approval For Cold/Flu Immunity Claims
FTC To Tailor Claim Substantiation Requirements To Each Case
FTC's First Probiotic Claims Case Emphasizes Need For Well-Designed Studies
Despite FTC's "Timid" Kellogg Action, Rigorous Claims Enforcement Expected
FDA's Flurry Of Food Claim Warnings Sends Bold Enforcement Message
FDA Cheerios Warning Signals Tougher Stance On Health Claims Enforcement
FDA Cheerios Warning Signals Tougher Stance On Health Claims Enforcement

Topics

Advertisement
UsernamePublicRestriction

Register

PS105254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel